FDA Inspection 1018004 — Summit Biosciences Inc.
The FDA completed an inspection of Summit Biosciences Inc. on June 23, 2017 in Lexington, KY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 23, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Lexington, KY (United States)